Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News
Financial Results · Q3 2026

Coya Therapeutics Q3 2026 Results: Net Loss of $10.6M, Loss Widens

Coya Therapeutics reported a net loss of $24.5 million for the nine months ended September 30, 2026, driven by a significant increase in research and development expenses. The company expressed substantial doubt about its ability to continue as a going concern, noting that its $35.8 million in cash and cash equivalents is insufficient to fund operations for more than one year.

Q3 2026 at a glance · $ million
MetricQ3 2026Q3 2025
Revenue0.23.6
Profit before tax-10.6-2.1
Net income-10.6-2.1
EPS (diluted, $ a share)$-0.45$-0.13

A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.

Growth and margins
Revenue, year on year-93.4%
Source

10-Q filed with the SEC, NASDAQ: COYA. Figures from the filing's XBRL data; summary written with AI assistance from the filing.

Read the filing ↗

Coya Therapeutics, Inc.: key numbers

Share price
$3.02Close, Nov 17
Market cap
$70.8M
Shares outstanding
23.46MLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834

Today's reference numbers, updated daily. Not a valuation or a recommendation.

More from Coya Therapeutics, Inc.

All →
8:02 AM ET 8-K
Financial Results

Coya Therapeutics Financial Results

Coya Therapeutics reported Q3 2026 financial results, highlighting the completion of enrollment in its Phase 2/3 ALSTARS trial for COYA 302 in ALS. The company ended the quarter with $35.8 million in cash, which it expects will fund operations into the second half of 2027, past the anticipated topline data readout in early Q2 2027.

Term
Q3 2026

“Completion of enrollment in our Phase 2/3 ALSTARS trial represents a significant achievement for Coya as we advance COYA 302 for the treatment of ALS. With topline data anticipated in early Q2 2027, we remain focused on communicating data from this study as soon as it is available.”

Arun Swaminathan, Ph.D., Chief Executive Officer of Coya Therapeutics

“Completion of the ALSTARS trial is an important milestone as we move forward in our quest for providing a potential therapy for this lethal disease. The addition of the open-label extension provides participants the opportunity to continue on COYA 302 while we continue to collect important data.”

Fred Grossman, DO, FAPA, President and Chief Medical Officer of Coya Therapeutics
8:30 AM ET 8-K
Business Update

Coya Therapeutics Business Update

Coya Therapeutics announced plans to initiate an open-label extension for its Phase 2/3 ALSTARS trial of COYA 302 in ALS to collect long-term safety and efficacy data. Due to resource prioritization for the ALS program, the company has delayed the planned initiation of its Phase 2 trial for COYA 302 in frontotemporal dementia from late 2026 to 2027.

8:30 AM ET 8-K
Clinical Trial Data

Coya Therapeutics Clinical Trial Data

Coya Therapeutics announced it has achieved full enrollment of 120 patients in its Phase 2/3 ALSTARS trial evaluating COYA 302 for the treatment of amyotrophic lateral sclerosis (ALS). The company expects to release topline data from the double-blind treatment phase in early Q2 2027.

8:15 AM ET 8-K
Business Update

Coya Therapeutics Business Update

Coya Therapeutics announced it has enrolled the 100th patient in its Phase 2/3 ALSTARS trial evaluating COYA 302 for the treatment of ALS. The company expects to complete full enrollment of 120 participants shortly and remains on track to report topline data in early Q2 2027.

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.